title: [Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week].
abstract: BACKGROUND
  An approach of daily or 5 days per week treatment as maintenance therapy is mandatory among HIV patients with CMV retinitis. We evaluate the efficacy and tolerance of thrice weekly maintenance therapy for CMV retinitis in AIDS patients.
  
  
  METHODS
  Sixty nine consecutive patients with CMV disease were eligible for a prospective open clinical trial. Thirty three completed the induction treatment of CMV retinitis, agreed on maintenance thrice weekly and were included. Twenty nine received Ganciclovir (10 mg/kg/day) and 4 foscarnet (100 mg/kg/day) thrice weekly.
  
  
  RESULTS
  The mean age was 34 years. Twenty nine of the 33 (87%) were males and 13 (39%) drug addicts. Mean CD4+ lymphocyte count at inclusion was 44 cells per relapsed and 22 (66%) died. The median time to relapse, survival free of CMV retinitis and the median survival was 18, 14 and 34 weeks respectively.
  
  
  CONCLUSIONS
  Since the outcome of our patients with thrice weekly maintenance therapy was similar to historical controls our study at least provides the rational for this hypothesis to be tested in a future randomised trial.
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona.
authors.forename: J
authors.initials: J
authors.lastname: Mallolas
authors.forename: J M
authors.initials: JM
authors.lastname: Gatell
authors.forename: J L
authors.initials: JL
authors.lastname: Gómez-Sirvent
authors.forename: E
authors.initials: E
authors.lastname: Buira
authors.forename: L
authors.initials: L
authors.lastname: Zamora
authors.forename: J
authors.initials: J
authors.lastname: Alecrim-Andrade
authors.forename: A
authors.initials: A
authors.lastname: Adán
authors.forename: M
authors.initials: M
authors.lastname: Morales
authors.forename: J M
authors.initials: JM
authors.lastname: Miró
authors.forename: M
authors.initials: M
authors.lastname: Lonća
authors.forename: A
authors.initials: A
authors.lastname: Guelar
authors.forename: E
authors.initials: E
authors.lastname: Soriano
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use*; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications / Q000401:mortality; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir
vernacular_title: Profilaxis secundaria de la retinitis por citomegalovirus en pacientes con sida: eficacia de una pauta intermitente de 3 días por semana.